Pacific Biosciences of California (PACB) PT Raised to $1.50 at Piper Sandler
Tweet
Share
E-mailGet Alerts PACB Hot Sheet
Price: $1.21 +5.22%
Rating Summary:
9 Buy, 11 Hold, 1 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 12 | Down: 23 | New: 22
Rating Summary:
9 Buy, 11 Hold, 1 Sell
Rating Trend:
Up
Today's Overall Ratings:
Up: 12 | Down: 23 | New: 22
Join SI Premium – FREE
Piper Sandler analyst Dave Westenberg raised the price target on Pacific Biosciences of California (NASDAQ: PACB) to $1.50 (from $1.25) while maintaining a Neutral rating.
You May Also Be Interested In
- Freedom Broker Upgrades PrimeEnergy Resource (PNRG) to Hold
- York Space Systems (YSS) PT Lowered to $15 at Jefferies
- Candel Therapeutics Inc. (CADL) PT Raised to $15 at Freedom Broker
Create E-mail Alert Related Categories
Analyst PT ChangeSign up for StreetInsider Free!
Receive full access to all new and archived articles, unlimited portfolio tracking, e-mail alerts, custom newswires and RSS feeds - and more!
